Limits upfront costs for oral anticancer medications for persons covered under certain health benefits plans.
Impact
If implemented, the legislation would significantly change how health insurance policies cover oral anticancer medications. With this bill, private and public health benefit plans would be required to not only provide equitable coverage for orally administered anticancer treatments compared to their intravenous counterparts but also eliminate additional cost barriers that may impede access to necessary medications. This can lead to a financial relief for patients who often face high out-of-pocket expenses when dealing with cancer treatments.
Summary
Assembly Bill A797 seeks to amend existing statutes concerning the coverage of orally administered anticancer medications under various health benefits plans in New Jersey. The primary aim of the bill is to limit the upfront costs that patients must pay for these medications, ensuring that they are treated no less favorably than intravenously administered or injected anticancer medications. Provisions include the stipulation that health insurance plans cannot impose additional upfront costs aside from standard copayments, deductibles, or coinsurance, aimed at alleviating the financial burden on patients in need of these critical medications.
Contention
The bill addresses an important concern regarding patient access to medications; however, stakeholders may have differing views on its implementation. Supporters argue that it is essential for combating the high costs associated with cancer treatment and improving patient outcomes by ensuring affordability of oral medications. Conversely, opponents, particularly from insurance sectors, may argue about potential impacts on insurance premiums and the sustainability of coverage mandates in the long-term.
Prohibits SHBP, SEHBP, and Medicaid from denying coverage for maintenance medications for chronic conditions for covered persons solely because of change in health benefits plan or pharmacy benefits manager.
Prohibits SHBP, SEHBP, and Medicaid from denying coverage for maintenance medications for chronic conditions for covered persons solely because of change in health benefits plan or pharmacy benefits manager.
Requires health care practitioners prescribing opioid medications to limit amount of prescribed medication to seven-day supply, except in certain circumstances.